These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 36577922)

  • 1. Sarcosine (glycine transporter inhibitor) attenuates behavioural and biochemical changes induced by ketamine, in the rat model of schizophrenia.
    Kumar A; Akhtar A; Kuhad A; Sah SP
    Exp Brain Res; 2023 Feb; 241(2):451-467. PubMed ID: 36577922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glycine transporter-1: a new potential therapeutic target for schizophrenia.
    Hashimoto K
    Curr Pharm Des; 2011; 17(2):112-20. PubMed ID: 21355838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of a glycine transporter-1 inhibitor and D-serine on MK-801-induced immobility in the forced swimming test in rats.
    Kawaura K; Koike H; Kinoshita K; Kambe D; Kaku A; Karasawa J; Chaki S; Hikichi H
    Behav Brain Res; 2015 Feb; 278():186-92. PubMed ID: 25300471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of glycine transporter I inhibitor, N-methylglycine (sarcosine), on ketamine-induced alterations in sensorimotor gating and regional brain c-Fos expression in rats.
    Yang SY; Hong CJ; Huang YH; Tsai SJ
    Neurosci Lett; 2010 Jan; 469(1):127-30. PubMed ID: 19944746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic potential and underlying mechanism of sarcosine (N-methylglycine) in N-methyl-D-aspartate (NMDA) receptor hypofunction models of schizophrenia.
    Pei JC; Hung WL; Lin BX; Shih MH; Lu LY; Luo DZ; Tai HC; Studer V; Min MY; Lai WS
    J Psychopharmacol; 2019 Oct; 33(10):1288-1302. PubMed ID: 31294644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sarcosine-Based Glycine Transporter Type-1 (GlyT-1) Inhibitors Containing Pyridazine Moiety: A Further Search for Drugs with Potential to Influence Schizophrenia Negative Symptoms.
    Harsing LG; Timar J; Szabo G; Udvari S; Nagy KM; Marko B; Zsilla G; Czompa A; Tapolcsanyi P; Kocsis A; Matyus P
    Curr Pharm Des; 2015; 21(17):2291-303. PubMed ID: 25578890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia.
    Tsai G; Lane HY; Yang P; Chong MY; Lange N
    Biol Psychiatry; 2004 Mar; 55(5):452-6. PubMed ID: 15023571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjunctive sarcosine plus benzoate improved cognitive function in chronic schizophrenia patients with constant clinical symptoms: A randomised, double-blind, placebo-controlled trial.
    Lin CY; Liang SY; Chang YC; Ting SY; Kao CL; Wu YH; Tsai GE; Lane HY
    World J Biol Psychiatry; 2017 Aug; 18(5):357-368. PubMed ID: 26691576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia.
    Lane HY; Huang CL; Wu PL; Liu YC; Chang YC; Lin PY; Chen PW; Tsai G
    Biol Psychiatry; 2006 Sep; 60(6):645-9. PubMed ID: 16780811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interactions between glycine transporter type 1 (GlyT-1) and some inhibitor molecules - glycine transporter type 1 and its inhibitors (review).
    Harsing LG; Zsilla G; Matyus P; Nagy KM; Marko B; Gyarmati Z; Timar J
    Acta Physiol Hung; 2012 Mar; 99(1):1-17. PubMed ID: 22425803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study.
    Lane HY; Chang YC; Liu YC; Chiu CC; Tsai GE
    Arch Gen Psychiatry; 2005 Nov; 62(11):1196-204. PubMed ID: 16275807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Supplementation of antipsychotic treatment with sarcosine – GlyT1 inhibitor – causes changes of glutamatergic (1)NMR spectroscopy parameters in the left hippocampus in patients with stable schizophrenia.
    Strzelecki D; Podgórski M; Kałużyńska O; Gawlik-Kotelnicka O; Stefańczyk L; Kotlicka-Antczak M; Gmitrowicz A; Grzelak P
    Neurosci Lett; 2015 Oct; 606():7-12. PubMed ID: 26306650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alterations in brain extracellular dopamine and glycine levels following combined administration of the glycine transporter type-1 inhibitor Org-24461 and risperidone.
    Nagy K; Marko B; Zsilla G; Matyus P; Pallagi K; Szabo G; Juranyi Z; Barkoczy J; Levay G; Harsing LG
    Neurochem Res; 2010 Dec; 35(12):2096-106. PubMed ID: 20725779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of D-cycloserine and sarcosine on in vivo frontal neural activity in a schizophrenia-like model.
    Yao L; Wang Z; Deng D; Yan R; Ju J; Zhou Q
    BMC Psychiatry; 2019 Oct; 19(1):314. PubMed ID: 31653237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. D-Serine and a glycine transporter-1 inhibitor enhance social memory in rats.
    Shimazaki T; Kaku A; Chaki S
    Psychopharmacology (Berl); 2010 Apr; 209(3):263-70. PubMed ID: 20198471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Supplementation of Antipsychotic Treatment with the Amino Acid Sarcosine Influences Proton Magnetic Resonance Spectroscopy Parameters in Left Frontal White Matter in Patients with Schizophrenia.
    Strzelecki D; Podgórski M; Kałużyńska O; Gawlik-Kotelnicka O; Stefańczyk L; Kotlicka-Antczak M; Gmitrowicz A; Grzelak P
    Nutrients; 2015 Oct; 7(10):8767-82. PubMed ID: 26506383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia.
    Singh SP; Singh V
    CNS Drugs; 2011 Oct; 25(10):859-85. PubMed ID: 21936588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of striatal dopamine release by glycine transport inhibitors.
    Javitt DC; Hashim A; Sershen H
    Neuropsychopharmacology; 2005 Apr; 30(4):649-56. PubMed ID: 15688094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adding Sarcosine to Antipsychotic Treatment in Patients with Stable Schizophrenia Changes the Concentrations of Neuronal and Glial Metabolites in the Left Dorsolateral Prefrontal Cortex.
    Strzelecki D; Podgórski M; Kałużyńska O; Stefańczyk L; Kotlicka-Antczak M; Gmitrowicz A; Grzelak P
    Int J Mol Sci; 2015 Oct; 16(10):24475-89. PubMed ID: 26501260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Sarcosine (a Glycine Transport 1 Inhibitor) and Risperidone (an Atypical antipsychotic Drug) on MK-801 Induced Learning and Memory Deficits in Rats.
    Kumar V; Ahmad MA; Najmi AK; Akhtar M
    Drug Res (Stuttg); 2016 Jan; 66(1):11-7. PubMed ID: 25710578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.